|Bid||0.1500 x 0|
|Ask||0.1550 x 0|
|Day's Range||0.1450 - 0.1550|
|52 Week Range||0.1200 - 0.2450|
|Beta (3Y Monthly)||1.43|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Doug Janzen has been the CEO of Aequus Pharmaceuticals Inc. (CVE:AQS) since 2014. First, this article will compare CEO...
If you love investing in stocks you're bound to buy some losers. But the last three years have been particularly tough on longer term Aequus Pharmaceuticals Inc. (CVE:AQS) shareholders. So they might be feeling emotional abou...
Doug Janzen has been the CEO of Aequus Pharmaceuticals Inc (CVE:AQS) since 2014. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then Read More...
A look at the shareholders of Aequus Pharmaceuticals Inc (CVE:AQS) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, Read More...